Kidney Cancer Trial, Recruiting NCT06908902 Sponsor: The First Affiliated Hospital with Nanjing Medical University Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT06908902
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Imaging (such as a scan) has confirmed a stage T1 kidney tumor (either T1a or T1b), and the treating doctor believes a surgery to remove part of the kidney would be beneficial.
  • People aged between 18 and 90 years.
  • People with no history of serious kidney disease or conditions where the immune system attacks the body.
  • Heart and lung health is strong enough to safely undergo major abdominal surgery.
  • People with an ECOG performance status score of 0 or 1, meaning they are fully active or have only minor restrictions on physical activity (confirm with trial site).
  • People who are willing to undergo a specific type of partial kidney removal surgery called zero-ischemia partial nephrectomy and are able to sign a written consent form agreeing to follow the study requirements.

Who may not be able to join:

  • Scans show the tumor is at stage T2 or higher (meaning it is larger or more advanced).
  • Scans suggest the tumor is located in a specific part of the kidney called the renal pelvis, or the tumor type is identified as a Wilms' tumor or similar.
  • The treating doctor considers the person unsuitable for partial kidney removal surgery.
  • Major surgery or a serious physical injury occurred within the 28 days before enrolling in the trial.
  • A live vaccine was received within 28 days before enrolling.
  • A serious ongoing or active infection requiring antibiotic, antifungal, or antiviral medication occurred within 14 days before enrolling.
  • Any traditional Chinese medicine or herbal supplements taken for cancer treatment within 14 days before enrolling.
  • People who are currently participating in any other clinical trials.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +8613951813528

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 December 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

serum creatinine

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov